<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772941</url>
  </required_header>
  <id_info>
    <org_study_id>A3051109</org_study_id>
    <nct_id>NCT00772941</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)</brief_title>
  <official_title>Drug Use Investigation Of Champix (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this surveillance is to collect information about 1) adverse drug reaction
      not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug
      reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy
      of this drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the first Varenicline(Champix) should be
      registered consecutively until the number of subjects reaches target number in order to
      extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Gender.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether gender is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Age.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether age is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether Chronic obstructive pulmonary disease as a complication is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Drugs.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether taking concomitant drugs is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether receiving concomitant therapies is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events to determine whether weight at baseline is a significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Related Adverse Events.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Varenicline. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Numbers of Treatment Related Adverse Events were evaluated in company with the causal relationship to Varenicline. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Continuous Abstinence Situation by 52 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of participants with dependence on Varenicline by 52 weeks. Varenicline-dependent Treatment Related Adverse Events are Feeling abnormal, Feeling drunk, Feeling jittery, Disturbance in attention, Dizziness, Memory impairment, Mental impairment, Psychomotor hyperactivity, Sedation, Somnolence, Confusional state, Depersonalisation, Disorientation, Dissociation, Euphoric mood, Mood variable, Mood swings, and Hallucination.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3939</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <description>Patients taking Varenicline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows.
&quot;The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks.&quot;</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Champix, Chantix</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients whom an investigator involving A3051109 prescribes the Varenicline(Champix).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients need to be administered Varenicline(Champix) in order to be enrolled in the
             surveillance.

        Exclusion Criteria:

          -  Patients not administered Varenicline(Champix).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3051109&amp;StudyName=Drug%20Use%20Investigation%20Of%20Varenicline%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2014</results_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Participants taking Varenicline according to Japanese Package Insert.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3939"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>CRFs not available</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study not completed</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visits</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>GPSP Violation</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Participants taking Varenicline according to Japanese Package Insert.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Gender.</title>
        <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether gender is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male participants taking Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female participants taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Gender.</title>
          <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether gender is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2179"/>
                <count group_id="O2" value="1078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Gender&quot;. The null hypothesis is that there is no difference between &quot;Male and Female&quot; in the frequency of Treatment Related Adverse Events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Age.</title>
        <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether age is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;65 Years</title>
            <description>Participants with &lt;65 years taking Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>&gt;=65 Years</title>
            <description>Participants with &gt;=65 years taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Age.</title>
          <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether age is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2768"/>
                <count group_id="O2" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Age&quot;. The null hypothesis is that there is no difference between &quot;&lt;65 years and &gt;=65 years&quot; in the frequency of Treatment Related Adverse Events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication.</title>
        <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether Chronic obstructive pulmonary disease as a complication is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline - With Chronic Obstructive Pulmonary Disease</title>
            <description>Participants with chronic obstructive pulmonary disease as a complication taking Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline - Without Chronic Obstructive Pulmonary Disease</title>
            <description>Participants without chronic obstructive pulmonary disease as a complication taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication.</title>
          <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether Chronic obstructive pulmonary disease as a complication is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="3211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Chronic obstructive pulmonary disease as a complication&quot;. The null hypothesis is that there is no difference between &quot;Varenicline with and without Chronic obstructive pulmonary disease as a complication&quot; in the frequency of Treatment Related Adverse Events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Concomitant Drugs.</title>
        <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether taking concomitant drugs is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline - With Concomitant Drugs</title>
            <description>Participants taking concomitant drugs while taking Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline - Without Concomitant Drugs</title>
            <description>Participants taking no concomitant drugs while taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Concomitant Drugs.</title>
          <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether taking concomitant drugs is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="738"/>
                <count group_id="O2" value="2519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;concomitant drugs&quot;. The null hypothesis is that there is no difference between &quot;Varenicline with and without concomitant drugs&quot; in the frequency of Treatment Related Adverse Events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Concomitant Therapies.</title>
        <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether receiving concomitant therapies is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline - With Concomitant Therapies</title>
            <description>Participants receiving concomitant therapies while taking Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline - Without Concomitant Therapies</title>
            <description>Participants receiving no concomitant therapies while taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events – Concomitant Therapies.</title>
          <description>Number of participants with Treatment Related Adverse Events of Varenicline to determine whether receiving concomitant therapies is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="3156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;concomitant therapies&quot;. The null hypothesis is that there is no difference between &quot;Varenicline with and without concomitant therapies&quot; in the frequency of Treatment Related Adverse Events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline.</title>
        <description>Number of participants with Treatment Related Adverse Events to determine whether weight at baseline is a significant risk factor.</description>
        <time_frame>24 weeks</time_frame>
        <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. The number of participants who provided weight data at baseline was 1700.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;40 kg at Baseline</title>
            <description>Participants whose weights at baseline were less than 40 kg.</description>
          </group>
          <group group_id="O2">
            <title>&gt;=40 kg and &lt;50 kg at Baseline</title>
            <description>Participants whose weights at baseline were more than or equal to 40 kg and less than 50 kg.</description>
          </group>
          <group group_id="O3">
            <title>&gt;=50 kg and &lt;60 kg at Baseline</title>
            <description>Participants whose weights at baseline were more than or equal to 50 kg and less than 60 kg.</description>
          </group>
          <group group_id="O4">
            <title>&gt;=60 kg and &lt;70 kg at Baseline</title>
            <description>Participants whose weights at baseline were more than or equal to 60 kg and less than 70 kg.</description>
          </group>
          <group group_id="O5">
            <title>&gt;=70 kg and &lt;80 kg at Baseline</title>
            <description>Participants whose weights at baseline were more than or equal to 70 kg and less than 80 kg.</description>
          </group>
          <group group_id="O6">
            <title>&gt;= 80 kg at Baseline</title>
            <description>Participants whose weights at baseline were more than or equal to 80 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline.</title>
          <description>Number of participants with Treatment Related Adverse Events to determine whether weight at baseline is a significant risk factor.</description>
          <population>The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. The number of participants who provided weight data at baseline was 1700.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="453"/>
                <count group_id="O4" value="497"/>
                <count group_id="O5" value="342"/>
                <count group_id="O6" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="110"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Weight at Baseline&quot;. The null hypothesis is that there is no association between &quot;Weight at Baseline and the frequency of Treatment Related Adverse Events&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Weight at Baseline&quot;. The null hypothesis is that there is no linear trend in the frequency of Treatment Related Adverse Events across increasing levels of Weight at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day.</title>
        <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
        <time_frame>24 weeks</time_frame>
        <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on daily tobacco consumption was 2827.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;=20 Cigarettes Per Day</title>
            <description>Participants with &lt;=20 cigarettes per day during treatment with Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>&gt;=21 and &lt;=40 Cigarettes Per Day</title>
            <description>Participants with &gt;=21 and &lt;=40 cigarettes per day during treatment with Varenicline according to Japanese Package Insert.</description>
          </group>
          <group group_id="O3">
            <title>&gt;=41 Cigarettes Per Day</title>
            <description>Participants with &gt;=41 cigarettes per day during treatment with Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day.</title>
          <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
          <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on daily tobacco consumption was 2827.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1637"/>
                <count group_id="O2" value="1082"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1299"/>
                    <measurement group_id="O2" value="817"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Tobacco consumption per day&quot;. The null hypothesis is that there is no association between &quot;Tobacco consumption per day and the efficacy of Varenicline&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Tobacco consumption per day&quot;. The null hypothesis is that there is no linear trend in the efficacy of Varenicline across increasing levels of tobacco consumption per day.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Proportion of Responders – Prolonged Administration After 12 Weeks.</title>
        <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
        <time_frame>24 weeks</time_frame>
        <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants in whom the prolonged administration of Varenicline after 12 weeks was confirmed was 2598.</population>
        <group_list>
          <group group_id="O1">
            <title>Administration Prolonged After 12 Weeks</title>
            <description>Participants with prolonged administration of Varenicline after 12 weeks according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Administration Not Prolonged After 12 Weeks</title>
            <description>Participants without prolonged administration of Varenicline after 12 weeks according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Proportion of Responders – Prolonged Administration After 12 Weeks.</title>
          <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
          <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants in whom the prolonged administration of Varenicline after 12 weeks was confirmed was 2598.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="2534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="1993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;prolonged administration after 12 weeks&quot;. The null hypothesis is that there is no difference between &quot;administration prolonged after 12 weeks and administration not prolonged after 12 weeks&quot; in the efficacy of Varenicline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.</title>
        <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
        <time_frame>24 weeks</time_frame>
        <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on concomitant administration of antipsychotics was 2842.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline - With Antipsychotics as a Concomitant Drug</title>
            <description>Varenicline with Antipsychotics as a Concomitant Drug</description>
          </group>
          <group group_id="O2">
            <title>Varenicline - Without Antipsychotics as a Concomitant Drug</title>
            <description>Varenicline without Antipsychotics as a Concomitant Drug</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug.</title>
          <description>The primary analysis item was &quot;the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.</description>
          <population>The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on concomitant administration of antipsychotics was 2842.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="2702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="2111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;antipsychotics as a concomitant drug&quot;. The null hypothesis is that there is no difference between &quot;Varenicline with and without antipsychotics as a concomitant drug&quot; in the efficacy of Varenicline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Related Adverse Events.</title>
        <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Varenicline. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <population>No statistical analysis provided for the frequency of treatment related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Participants taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Adverse Events.</title>
          <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Varenicline. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
          <population>No statistical analysis provided for the frequency of treatment related adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.</title>
        <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Numbers of Treatment Related Adverse Events were evaluated in company with the causal relationship to Varenicline. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
        <time_frame>24 weeks</time_frame>
        <population>No statistical analysis provided for the frequency of unlisted treatment related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Participants taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert.</title>
          <description>Adverse events mean all unfavorable events that occur in participants after administration of Varenicline, irrespective of causal relationship to Varenicline (including clinically problematic abnormal changes in laboratory test values). Numbers of Treatment Related Adverse Events were evaluated in company with the causal relationship to Varenicline. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert. The safety was evaluated on the first visit after 24 weeks; however, it was evaluated on the last visit for those who had stopped visiting before 24 weeks.</description>
          <population>No statistical analysis provided for the frequency of unlisted treatment related adverse events.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Continuous Abstinence Situation by 52 Weeks.</title>
        <description>Number of participants with dependence on Varenicline by 52 weeks. Varenicline-dependent Treatment Related Adverse Events are Feeling abnormal, Feeling drunk, Feeling jittery, Disturbance in attention, Dizziness, Memory impairment, Mental impairment, Psychomotor hyperactivity, Sedation, Somnolence, Confusional state, Depersonalisation, Disorientation, Dissociation, Euphoric mood, Mood variable, Mood swings, and Hallucination.</description>
        <time_frame>52 weeks</time_frame>
        <population>No statistical analysis provided for the frequency of Varenicline-dependent treatment related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Participants taking Varenicline according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Continuous Abstinence Situation by 52 Weeks.</title>
          <description>Number of participants with dependence on Varenicline by 52 weeks. Varenicline-dependent Treatment Related Adverse Events are Feeling abnormal, Feeling drunk, Feeling jittery, Disturbance in attention, Dizziness, Memory impairment, Mental impairment, Psychomotor hyperactivity, Sedation, Somnolence, Confusional state, Depersonalisation, Disorientation, Dissociation, Euphoric mood, Mood variable, Mood swings, and Hallucination.</description>
          <population>No statistical analysis provided for the frequency of Varenicline-dependent treatment related adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The frequency of treatment related adverse events during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Participants taking Varenicline according to Japanese Package Insert.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA-J 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA-J 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="708" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="397" subjects_affected="397" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Social avoidant behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Bulimia nervosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Lactation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

